Only 10–20% of CRC patients are responsive to anti-EGFR treatment, and the KRAS/NRAS mutational status is the standard-of-care biomarker to exclude patients from therapies based on anti-EGFR anti-bodies [51]. Here, KRAS is linked to colorectal carcinoma.